fda compounding glp 1 FDA's compounded GLP-1 limits will have ripple effects throughout the retail industry FDA Proposes Ban on Bulk
Description
Abstract Peptide therapeutics are increasingly used in the treatment of disease, but their administration by injection reduces patient compliance and convenience, especially for chronic diseases
2022Oct;15(189):15562

It is a once-weekly investigational triple agonist designed to activate three metabolic receptor pathways at the same time: GLP-1, GIP, and glucagon

Note that at higher doses, we tend to see more problems with side-effects like nausea, diarrhea, stomach upset, etc., so why put yourself through that

Weight loss typically plateaus somewhere between months 12 and 18
